Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (1091)	12/18/1997 12:42:00 AM
From: BDR	Read Replies (2) \| Respond to of 7041

Thanks for the posts. I was hoping that some of the results from recent Phase II, III trials would be available somewhere. Everyone is talking about how wonderful/horrible the results are depending on which side you are on but where's the data? I spoke with a Zonagen rep at the AUA national meeting last April and saw the results of a small early trial. There must be other studies since then. I hashed out the issue of safety six months ago on the VVUS thread (remember TUNA's "killer drug"-where is that shill these days with VVUS at 11-BUY BUY BUY it's going to 400!!)) and I think hypotension and the safety profile are issues but not overwhelming. I think the biggest concern were I long would be the apparent lack of patent protection for the product. If I were a big pharmaceutical house I would just lay low in the weeds, let ZONA do the grunt work of getting this approved and if it is a winner ram up to produce a knock off me-too drug. If not, ZONA sinks back into the ooze and life goes on without any effort being spent on phentolamine.